Cytosorbents (NASDAQ:CTSO) Earns "Buy" Rating from D. Boral Capital

Key Points

• D. Boral Capital has reaffirmed a "buy" rating for Cytosorbents (NASDAQ:CTSO) with a target price of $10.00 per share, indicating potential for significant growth.
• Cytosorbents has reported a net margin of -41.77% and a revenue slightly below estimates, with the company facing ongoing financial challenges.
• Institutional investors have increased their stakes in Cytosorbents, with Goldman Sachs Group boosting its position by 149.2% in the first quarter.

Cytosorbents (NASDAQ:CTSO - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at D. Boral Capital in a report released on Friday,Benzinga reports. They presently have a $10.00 price objective on the medical research company's stock.

Other equities research analysts have also issued reports about the stock. HC Wainwright reaffirmed a "neutral" rating and set a $1.00 price target on shares of Cytosorbents in a report on Thursday, May 15th. Wall Street Zen started coverage on Cytosorbents in a report on Wednesday, May 21st. They set a "hold" rating on the stock.

Cytosorbents Price Performance

CTSO stock traded down $0.13 during mid-day trading on Friday, hitting $1.07. The stock had a trading volume of 153,064 shares, compared to its average volume of 192,395. The company has a current ratio of 2.61, a quick ratio of 2.30 and a debt-to-equity ratio of 0.98. Cytosorbents has a 52 week low of $0.71 and a 52 week high of $1.61. The firm has a market capitalization of $67.15 million, a P/E ratio of -6.29 and a beta of 1.19. The firm has a fifty day simple moving average of $1.06 and a 200 day simple moving average of $1.03.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.02. Cytosorbents had a negative net margin of 25.58% and a negative return on equity of 109.15%. The firm had revenue of $9.62 million for the quarter, compared to analyst estimates of $9.79 million. As a group, research analysts forecast that Cytosorbents will post -0.3 EPS for the current year.

Institutional Investors Weigh In On Cytosorbents

Hedge funds have recently modified their holdings of the company. Millennium Management LLC acquired a new stake in Cytosorbents during the 4th quarter worth approximately $30,000. Goldman Sachs Group Inc. boosted its position in Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company's stock worth $63,000 after buying an additional 37,519 shares during the period. Key Client Fiduciary Advisors LLC boosted its position in Cytosorbents by 127.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock worth $78,000 after buying an additional 43,900 shares during the period. Renaissance Technologies LLC boosted its position in Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock worth $80,000 after buying an additional 8,400 shares during the period. Finally, Northern Trust Corp boosted its position in Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after buying an additional 16,701 shares during the period. Institutional investors and hedge funds own 32.87% of the company's stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.